阴道炎治疗药物的全球市场规模、份额和成长分析：按类型、治疗方法和分销管道 - 行业预测（2024-2031）

2022年全球阴道炎治疗药物市场规模将为4.4亿美元，预测期内（2024-2031年）复合年增长率为25.6%，从2023年的5.5亿美元增至2031年的5.5亿美元。预计将成长至2022年的5.5亿美元。34.2 亿。

随着越来越多的人患有阴道感染疾病，全球阴道感染疾病治疗市场正在不断扩大。市场正在转向个人化和微创治疗，重点是抗生素和益生菌的使用。新技术正在帮助开发诊断感染疾病的新治疗方法和工具。市场上的领先公司花钱进行研究，并与其他公司合作创造更多产品。北美和欧洲占据了大部分市场，因为它们拥有更好的医疗保健系统，人们对感染疾病有所了解。然而，随着越来越多的人获得医疗保健并了解这些感染疾病，快速发展的亚太国家预计将显着增长。

目录

执行摘要

• 市场概况
• 命运之轮

调查方法

• 资讯采购
• 次要/一级资讯来源
• 市场规模估算
• 市场假设与限制

母市场分析

• 市场概况
• 市场规模
• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务

主要市场考察

• 技术分析
• 价格分析
• 供应链分析
• 价值链分析
• 市场生态系统
• 智慧财产权分析
• 贸易分析
• Start-Ups分析
• 原料分析
• 创新矩阵
• 研发线产品分析
• 总体经济指标
• 主要投资分析
• 关键成功因素
• 竞争程度

市场动态及展望

• 市场动态
  • 促进因素
  • 机会
  • 抑制因素
  • 任务
• 监管环境
• 波特的分析
• 对未来中断的特殊考虑

全球阴道炎治疗药物市场：按类型

• 市场概况
• 细菌性阴道炎
• 酵母菌感染疾病
• 滴虫病

全球阴道炎治疗药物市场：治疗方法

• 市场概况
• 抗真菌药物和抗生素药物
• 局部霜
• 家庭治疗

全球阴道炎治疗药物市场：依分销管道划分

• 市场概况
• 药局
• 电子商务
• 零售店

全球阴道炎治疗药物市场规模：按地区划分

• 市场概况
• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东和非洲 (MEA)
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲地区

竞争格局

• 前5名企业对比
• 主要企业市场定位（2021年）
• 主要市场参与者所采取的策略
• 关键成功策略
• 近期市集活动
• 主要企业市场占有率（2021年）

主要企业简介

• Pfizer Inc.（USA）
• Johnson & Johnson（USA）
• Novartis AG（Switzerland）
• GlaxoSmithKline plc（UK）
• Bayer AG（Germany）
• Sanofi（France）
• Merck & Co., Inc.（USA）
• Eli Lilly and Company（USA）
• AstraZeneca plc（UK/Sweden）
• AbbVie Inc.（USA）
• Gilead Sciences, Inc.（USA）
• Roche Holding AG（Switzerland）
• Bristol Myers Squibb（USA）
• Teva Pharmaceutical Industries Ltd.（Israel）
• Astellas Pharma Inc.（Japan）
• Mylan NV（USA）
• Daiichi Sankyo Co., Ltd.（Japan）
• Takeda Pharmaceutical Company Limited（Japan）
• Boehringer Ingelheim（Germany）
• Sun Pharmaceutical Industries Ltd.（India）

Global Vaginitis Therapeutics market size was valued at USD 0.44 billion in 2022 and is poised to grow from USD 0.55 billion in 2023 to USD 3.42 billion by 2031, at a CAGR of 25.6% during the forecast period (2024-2031).

The worldwide market for treating vaginal infections is growing because more people are getting these infections. The market is moving towards treatments that are personalized and less invasive, with a focus on using antimicrobial drugs and probiotics. New technology is helping create new treatments and tools for diagnosing infections. Big companies in the market are spending money on research and working with others to make more products. North America and Europe have big parts of the market because they have good healthcare systems and people know about these infections. But countries in Asia-Pacific that are developing quickly could see big growth because more people are getting access to healthcare and learning about these infections.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Vaginitis Therapeutics Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Vaginitis Therapeutics Market Segmental Analysis

The global vaginitis therapeutics market is segmented on the basis of type, treatment, distribution channel, and region. By Type, the market is segmented into bacterial vaginosis, yeast infection, and trichomoniasis. By Treatment, the market is segmented into antifungal and antibiotic medications, topical creams, and home remedies. By Distribution channel, the market is segmented into pharmacies, e-commerce, and retail stores. By Region, the market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.

Drivers of the Global Vaginitis Therapeutics Market

Vaginitis, which includes different types of vaginal infections and inflammation, is a common problem for women all over the world. Many women have it, so there's a big need for treatments that work well. Things like not keeping clean, using some types of birth control, taking antibiotics, and changes in hormones can make vaginitis more likely to happen.

Restraints in the Global Vaginitis Therapeutics Market

Antibiotics are often used to treat bacterial vaginosis, a type of vaginitis. But using antibiotics too much or not in the right way has made some bacteria become resistant to them. This means antibiotics might not work as well to treat bacterial vaginosis, and it can be harder to manage the infection.

Market Trends of the Global Vaginitis Therapeutics Market

A big trend in treating vaginal infections is that more women are learning about their reproductive health. They want to know more about how to find out if they have an infection, how to treat it, and how to stop it from happening again. Because of this, more women might see a doctor early on if they think they have an infection, which means there's a bigger need for treatments that work well.

Table of Contents

Executive Summary

• Market Overview
• Wheel of Fortune

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Parent Market Analysis

• Market Overview
• Market Size
• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges

Key Market Insights

• Technology Analysis
• Pricing Analysis
• Supply Chain Analysis
• Value Chain Analysis
• Ecosystem of the Market
• IP Analysis
• Trade Analysis
• Startup Analysis
• Raw Material Analysis
• Innovation Matrix
• Pipeline Product Analysis
• Macroeconomic Indicators
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Regulatory Landscape
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers
• Skyquest Special Insights on Future Disruptions
  • Political Impact
  • Economic Impact
  • Social Impact
  • Technical Impact
  • Environmental Impact
  • Legal Impact

Global Vaginitis Therapeutics Market by Type

• Market Overview
• Bacterial vaginosis
• yeast infection
• and trichomoniasis

Global Vaginitis Therapeutics Market by Treatment

• Market Overview
• Antifungal and antibiotic medications
• topical creams
• and home remedies

Global Vaginitis Therapeutics Market by Distribution channel

• Market Overview
• Pharmacies
• e-commerce
• and retail stores

Global Vaginitis Therapeutics Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2021
• Strategies Adopted by Key Market Players
• Top Winning Strategies
  • By Development
  • By Company
  • By Year
• Recent Activities in the Market
• Key Companies Market Share (%), 2021

Key Company Profiles

• Pfizer Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc (UK/Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Gilead Sciences, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol Myers Squibb (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Astellas Pharma Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Mylan N.V. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Daiichi Sankyo Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sun Pharmaceutical Industries Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments